12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ficlatuzumab: Phase II data

Data from 188 patients with previously untreated NSCLC in the Phase II portion of an open-label, Asian Phase Ib/II trial showed that first-line treatment with ficlatuzumab plus gefitinib missed the primary endpoint of improving ORR vs. gefitinib alone (43% vs. 40%, p-value not disclosed). Ficlatuzumab plus gefitinib also missed the secondary endpoint of median PFS vs. gefitinib alone (5.6 vs. 4.7 months, p-value not disclosed).

In a subgroup of patients with EGFR-sensitizing mutations and low levels of c-Met receptor tyrosine kinase expression (n=19), ficlatuzumab plus gefitinib non-significantly improved ORR (70% vs. 44%) and median PFS vs....

Read the full 475 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >